|
1
|
Mori K, Matsumoto K, Ikeda M, Koguchi D, Shimizu Y, Tsumura H, Ishii D, Tsuji S, Sato Y, Iwamura M. Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer. Diagnostics (Basel) 2023; 13:3067. [PMID: 37835810 PMCID: PMC10572329 DOI: 10.3390/diagnostics13193067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 09/21/2023] [Accepted: 09/25/2023] [Indexed: 10/15/2023] Open
Abstract
OBJECTIVE To investigate the correlation between total protein expression of heart development protein with EGF-like domain 1 (HEG1) and clinicopathological characteristics in patients with bladder cancer (BC) after radical cystectomy (RC). PATIENTS AND METHODS We retrospectively analyzed data from 110 patients who underwent RC at Kitasato University Hospital. And we prepared an anti-HEG1 monoclonal antibody W10B9, which can detect total HEG1 protein. HEG1 protein expression in tumor cells was evaluated separately for membrane and cytoplasmic staining using immunohistochemistry. RESULTS Membranous HEG1 expression was associated with absent lymphovascular invasion (p < 0.01) and low pT stage (p < 0.01). Kaplan-Meier analysis revealed that the membranous HEG1-positive group had significantly long recurrence-free survival (RFS) (p < 0.01) and cancer-specific survival (p = 0.01). Expression of membranous HEG1 was identified as an independent prognostic factor for RFS (p = 0.04). There were no significant differences between cytoplasmic HEG1 expression and clinicopathologic factors including prognosis. CONCLUSION The expression of membranous HEG1 could serve as a favorable prognostic indicator in patients with BC treated with RC.
Collapse
Affiliation(s)
- Kohei Mori
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| | - Kazumasa Matsumoto
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| | - Masaomi Ikeda
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| | - Dai Koguchi
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| | - Yuriko Shimizu
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| | - Hideyasu Tsumura
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| | - Daisuke Ishii
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| | - Shoutaro Tsuji
- Department of Medical Technology & Clinical Engineering, Gunma University of Health and Welfare, 191-1 Kawamagari-machi, Maebashi-shi 371-0823, Gunma, Japan;
| | - Yuichi Sato
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
- KITASATO-OTSUKA Biomedical Assay Laboratories Co., Ltd., 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0329, Kanagawa, Japan
| | - Masatsugu Iwamura
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (K.M.); (M.I.); (D.K.); (Y.S.); (H.T.); (D.I.); (Y.S.); (M.I.)
| |
Collapse
|
|
2
|
Zhu H, Wang Z, Wang W, Lu Y, He YW, Tian J. Bacterial Quorum-Sensing Signal DSF Inhibits LPS-Induced Inflammations by Suppressing Toll-like Receptor Signaling and Preventing Lysosome-Mediated Apoptosis in Zebrafish. Int J Mol Sci 2022; 23:ijms23137110. [PMID: 35806111 PMCID: PMC9266882 DOI: 10.3390/ijms23137110] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 06/17/2022] [Accepted: 06/23/2022] [Indexed: 12/15/2022] Open
Abstract
Bacteria and their eukaryotic hosts have co-evolved for millions of years, and the former can intercept eukaryotic signaling systems for the successful colonization of the host. The diffusible signal factor (DSF) family represents a type of quorum-sensing signals found in diverse Gram-negative bacterial pathogens. Recent evidence shows that the DSF is involved in interkingdom communications between the bacterial pathogen and the host plant. In this study, we explored the anti-inflammatory effect of the DSF and its underlying molecular mechanism in a zebrafish model. We found that the DSF treatment exhibited a strong protective effect on the inflammatory response of zebrafish induced by lipopolysaccharide (LPS). In the LPS-induced inflammation zebrafish model, the DSF could significantly ameliorate the intestinal pathological injury, reduce abnormal migration and the aggregation of inflammatory cells, inhibit the excessive production of inflammatory mediator reactive oxygen species (ROS) content, and prevent apoptosis. Through an RNA-Seq analysis, a total of 938 differentially expressed genes (DEGs) was screened between LPS and LPS + DSF treatment zebrafish embryos. A further bioinformatics analysis and validation revealed that the DSF might inhibit the LPS-induced zebrafish inflammatory response by preventing the activation of signaling in the Toll-like receptor pathway, attenuating the expression of pro-inflammatory cytokines and chemokines, and regulating the activation of the caspase cascade through restoring the expression of lysosomal cathepsins and apoptosis signaling. This study, for the first time, demonstrates the anti-inflammatory role and a potential pharmaceutical application of the bacterial signal DSF. These findings also suggest that the interkingdom communication between DSF-producing bacteria and zebrafish might occur in nature.
Collapse
Affiliation(s)
- Hongjie Zhu
- Zebrafish Model Research Center for Human Diseases and Drug Screening in Western China, School of Medicine, The College of Life Sciences, Northwest University, Xi’an 710069, China; (H.Z.); (Z.W.); (W.W.); (Y.L.)
| | - Zhihao Wang
- Zebrafish Model Research Center for Human Diseases and Drug Screening in Western China, School of Medicine, The College of Life Sciences, Northwest University, Xi’an 710069, China; (H.Z.); (Z.W.); (W.W.); (Y.L.)
| | - Wenxin Wang
- Zebrafish Model Research Center for Human Diseases and Drug Screening in Western China, School of Medicine, The College of Life Sciences, Northwest University, Xi’an 710069, China; (H.Z.); (Z.W.); (W.W.); (Y.L.)
| | - Yongbo Lu
- Zebrafish Model Research Center for Human Diseases and Drug Screening in Western China, School of Medicine, The College of Life Sciences, Northwest University, Xi’an 710069, China; (H.Z.); (Z.W.); (W.W.); (Y.L.)
| | - Ya-Wen He
- State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Development Sciences, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
- Correspondence: (Y.-W.H.); (J.T.); Tel.: +86-135-6438-5795 (Y.-W.H.); +86-29-88302339 (J.T.)
| | - Jing Tian
- Zebrafish Model Research Center for Human Diseases and Drug Screening in Western China, School of Medicine, The College of Life Sciences, Northwest University, Xi’an 710069, China; (H.Z.); (Z.W.); (W.W.); (Y.L.)
- Correspondence: (Y.-W.H.); (J.T.); Tel.: +86-135-6438-5795 (Y.-W.H.); +86-29-88302339 (J.T.)
| |
Collapse
|